Novo Nordisk stock tests recovery as Wegovy lifts 2026 outlook
Published on 11/09/2026 at 17:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGuidance improves while risks remain
- Novo Nordisk raised its 2026 adjusted sales and operating profit outlook after stronger GLP-1 momentum.
- Wegovy pill demand supports the obesity portfolio, while US pressure, competition and one-off charges remain important investor risks.
Novo Nordisk raised its 2026 outlook on Wednesday, November 4, after stronger third-quarter momentum in its GLP-1 portfolio. The company now expects adjusted sales growth and adjusted operating profit growth of minus 2 percent to plus 2 percent at constant exchange rates, compared with the previous range of minus 6 percent to zero.
The updated outlook reflects higher expectations for GLP-1 product sales. In the nine months through September 30, adjusted third-quarter sales rose 4 percent at constant exchange rates to DKK 79.195 billion, while adjusted operating profit increased 27 percent to DKK 31.720 billion, according to Novo Nordisk.
Wegovy pill drives the recovery case
Wegovy pill sales reached DKK 5.394 billion in the third quarter. The treatment had launched in four markets by the end of the quarter, and Novo Nordisk later expanded the rollout to eight markets. Management expects availability in more than 20 markets by the first half of 2027.
The portfolio is showing a mixed regional picture. The outlook assumes international sales growth but a decline in the United States. Pricing, market access and competition therefore remain central to whether the oral treatment can offset pressure on the established injectable business.
Impairments cloud reported performance
The adjusted improvement does not translate directly into reported operating profit. Novo Nordisk recognised DKK 8.7 billion in non-cash impairment charges linked to ziltivekimab and the right-sizing of its manufacturing network. Reported operating profit consequently fell 9 percent at constant exchange rates in the quarter, while the adjusted figure increased.
Novo Nordisk stock traded at 36.61 euros on Lang & Schwarz at 17:49 CET on Monday, November 9, 2026.
The next strategic milestone is the planned US launch of CagriSema in early 2027, subject to regulatory approval. For investors, the higher outlook strengthens the recovery case, but the expected US decline and intense obesity-drug competition keep execution risk high.
Broader European trading is covered in Current market reports.
More news and analyses on Novo Nordisk stock.
Novo Nordisk stock facts
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Lang & Schwarz price: EUR 36.61 at 17:49 CET on November 9, 2026
- 2026 adjusted outlook: Sales and operating profit growth of minus 2 percent to plus 2 percent at constant exchange rates
- Third-quarter adjusted sales: DKK 79.195 billion
- Third-quarter adjusted operating profit: DKK 31.720 billion
